SRTA vs TBI

For growth investors, TrueBlue, Inc.

(TBI) is the stronger pick with 3. 1% revenue growth year-over-year, versus -20. 7% for Strata Critical Medical, Inc. (SRTA). Strata Critical Medical, Inc. (SRTA) offers the better valuation at 10. 7x trailing P/E, making it the more compelling value choice. Analysts rate Strata Critical Medical, Inc. (SRTA) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Strata Critical Medical, Inc.

(SRTA) delivered a total return of -38. 6%, compared to -78. 7% for TrueBlue, Inc. (TBI). Over 10 years, the gap is even starker: SRTA returned -45. 2% versus TBI's -68. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TrueBlue, Inc.

(TBI) is the lower-risk stock at 1. 13β versus Strata Critical Medical, Inc. 's 2. 47β — meaning SRTA is approximately 117% more volatile than TBI relative to the S&P 500. On balance sheet safety, Strata Critical Medical, Inc. (SRTA) carries a lower debt/equity ratio of 1% versus 62% for TrueBlue, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TrueBlue, Inc.

(TBI) is pulling ahead at 3. 1% versus -20. 7% for Strata Critical Medical, Inc. (SRTA). On earnings-per-share growth, the picture is similar: Strata Critical Medical, Inc. grew EPS 242. 9% year-over-year, compared to 61. 4% for TrueBlue, Inc.. Over a 3-year CAGR, SRTA leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Strata Critical Medical, Inc.

(SRTA) is the more profitable company, earning 21. 0% net margin versus -3. 0% for TrueBlue, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TBI leads at -1. 7% versus -11. 3% for SRTA. At the gross margin level — before operating expenses — TBI leads at 21. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, TrueBlue, Inc.

(TBI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13)). Strata Critical Medical, Inc. (SRTA) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TBI: -68. 4%, SRTA: -45. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SRTA is a small-cap deep-value stock; TBI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.